Five Guys Selects FoodLogiQ to Connect Global Supply Chain

Leading burger franchise will leverage FoodLogiQ's supplier management and reporting solutions

DURHAM, N.C., April 25, 2017 /PRNewswire/ -- FoodLogiQ, the leading SaaS provider of food safety compliance, whole chain traceability, and supply chain transparency solutions, announced today Five Guys Burgers and Fries has selected its FoodLogiQ Connect platform for global supply chain visibility, streamlined supplier management, and quality issue tracking and reporting.

For over 30 years, Five Guys has served America with a strong commitment to fresh ingredients and a positive casual dining experience. As leaders in the "better burger" category, the chain of restaurants has quickly expanded to more than 1,400 locations across North America, Europe, and the Middle East.

Driven by this rapid growth, Five Guys required a supply chain solution that could meet its growing supplier management and food quality needs. The global restaurant brand will leverage the FoodLogiQ Connect platform to centralize supplier communications, standards and benchmarking. Using FoodLogiQ's Manage + Monitor module, Five Guys will standardize and centralize their international supplier food safety program and product quality specifications for their U.S., International (Europe and Middle East), and joint venture business in England.

"We truly have vendors who are partners in the business with us, and our suppliers make up the fabric of our brand," said Carl Napiwocki, VP Global Supply Chain. "FoodLogiQ enables us to build greater collaboration and visibility with our suppliers so that we can not only protect the Five Guys brand, but protect our suppliers as well."

"We are excited to add Five Guys to our growing list of customers answering the call for greater transparency from their consumers," said Dean Wiltse, CEO of FoodLogiQ. "The ease of use of the FoodLogiQ platform allows Five Guys to realize a return on investment by creating efficiencies in their supply chain while also providing the visual and analytical reporting that will drive strategic decisions for their business."

For more information, please visit and

About Five Guys

Five Guys is a family owned and operated franchise restaurant group that focuses on serving high-quality burgers and fries in a clean, no frills atmosphere. Five Guys was established in 1986 in Arlington, VA. In 2003, Five Guys opened its first franchised location and with the help of loyal franchisees, Five Guys has expanded from five to more than 1,400 locations worldwide.  Five Guys continues to be awarded "best" burger across various markets and ZAGAT Survey said "there are no better burgers."  For more information, visit

About FoodLogiQ

FoodLogiQ® LLC is a leading SaaS provider of food safety compliance, traceability, and supply chain transparency solutions. We help restaurant operators, food retailers and other food companies achieve end-to-end traceability while supporting safe and high quality food products across the supply chain. FoodLogiQ Connect is an online supplier community used by food companies to manage quality, safety, audit, regulatory compliance and traceability needs across their supply chains. To meet mounting regulatory requirements and consumer demands for transparency, food companies are leveraging FoodLogiQ Connect to validate supplier compliance with food safety and act with confidence in the event of a food safety or quality issue. To request a demo, please visit


Momentous Entertainment Group to Acquire Mobile Ad Network BLACKFOX

BLACKFOX to Provide Additional Domestic as well as Worldwide Revenue Streams

LAS VEGAS, NV – (NewMediaWire) – April 25, 2017 – Momentous Entertainment Group, Inc. („Momentous”) (OTCBB: MMEG), an online social media network company vertically organized into four business areas: social networking, social gaming, ecommerce sold consumer products and services, and OTT streaming media content creation and distribution, announced today that it has executed a Letter of Intent to acquire BLACKFOX.IO („BLACKFOX”). 

BLACKFOX.IO is a mobile advertising network with a strong worldwide affiliate network. BLACKFOX experienced explosive growth in 2015 through over a dozen premium and big-budget advertisers. BLACKFOX has a unqiue competitive advantage in that their customers only pay for performance for sucssesful installs or generated purchases. In addition, BLACKFOX clients are allowed to pay on credit terms (after a credit check). With mobile advertising on the rise, BLACKFOX is well positioned to offer advertisers a risk-free opportunity to capitalize on this growing niche. The biggest opportunity readily available to Momentous is BLACKFOX’s ability to quickly scale as BLACKFOX has hundreds of pending affiliates applications wanting to use and make money via their ad platform.

In business since 2014, with 12 employees, BLACKFOX continues to thrive and has seen extraordinary growth since inception. Since 2014, the company has had constant growing evergreen revenue. What makes this business evergreen is primarily due to the fact that mobile advertising is now on the rise and BLACKFOX provides a risk free service to help well established and new companies grow their user base by only paying for the successful performance of their product promotion and advertising. .

Momentous CEO Kurt Neubauer stated, „This brings a fourth acquisition to Momentous and adds yet another revenue stream to enhance our overall top and bottom line revenues. Momentous is utilizing both sides of the market equation, having a large worldwide base of social media subscribers and/or customers and identifying and acquiring ecommerce and other products and services that will appeal to those user bases. We are continuing to work our acquisition model and expect to continue this process throughout the year.”


BLACKFOX.IO is a unique mobile ad networks company that has been silently innovating the performance digital marketing sector by delivering highly qualified sales and leads to our trusted clients. BLACKFOX’s team has combined over 20 years experience in the performance marketing space and within that time frame they’ve generated millions of dollars for their clients. They work with their clients to create tailored marketing campaigns to find the perfect audience.

 About Momentous Entertainment Group (MMEG)

Momentous Entertainment Group, Inc. (MMEG) is an online social media network company. It is vertically organized into four business areas: social networking, social gaming, ecommerce sold consumer products and services, and OTT (Over-The-Top) streaming media content creation and distribution. 

With more than 11 million online registered users worldwide, Momentous’ value proposition serves multiple stakeholders: 1) Social network users, 2) OTT streaming content users, 3) Online gamers, and 4) Consumers looking to buy products and services through our e-commerce portal and our social network. 

Please note the Company may use social media to communicate with the public. This communication may include information that could be deemed material information. As a result, the Company encourages interested parties to review the information that it posts on the following social media channels: Facebook (, Twitter (, and LinkedIn (

To learn more, visit Momentous Entertainment Group’s websites: Corporate Site, Music Site and Music One Corp

Forward-Looking Statements

This press release may contain forward-looking statements, including information about management’s view of Momentous Entertainment Group Inc’s (MMEG) future expectations, plans and prospects. In particular, when used in the preceding discussion, the words „believes,” „expects,” „intends,” „plans,” „anticipates,” or „may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of MMEG to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in documents MMEG files with the Securities and Exchange Commission, including but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. Other unknown or unpredictable factors also could have material adverse effects on MMEG’s future results. The forward-looking statements included in this press release are made only as of the date hereof. MMEG cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, MMEG undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by MMEG.

Kalytera Therapeutics Inc. (QUEZF: OTCQB) | Kalytera Identifies Sites for Planned GvHD Clinical Trials; Company’s Research Gains Support at EBMT 2017

Apr 25, 2017

OTC Disclosure & News Service

VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSXV:KALY), a clinical-stage biopharmaceutical company developing next-generation cannabinoid-derived therapeutics, today announced that it has developed the multi-center location component of the plan for the proposed clinical trials to evaluate cannabidiol (“CBD”) for the prevention and treatment of Graft versus Host Disease (“GvHD”). Kalytera is developing this clinical trial plan with the intent of obtaining FDA and EMEA approval for commercialization.

Kalytera expects to finalize and publish the details of its clinical trial plan during the current quarter ending June 30, 2017. The plan will include the clinical trial designs, the anticipated timelines for initiation and completion, as well as the principal endpoints. The trials are intended to build on the encouraging data seen in the recently completed Phase 2a Clinical Trial.

In March 2017, Dr. Andrew L. Salzman, Kalytera’s Chief Executive Officer, and Dr. Sari Prutchi Sagiv, Kalytera’s Vice President of Scientific Operations, attended the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (“EBMT”) in Marseilles, France. Prior to joining Kalytera, Dr. Sagiv led the CBD-GvHD clinical research program at Talent Biotechs (“Talent”); Talent was acquired by Kalytera in February 2017.

The EBMT Annual Meeting brings together thought leaders from Europe and the world to explore the latest allogenic hematopoietic stem cell transplantation (“HCT”) and cellular therapy research. Having met and conferred with many of the leading authorities at EBMT, Drs. Salzman and Sagiv have developed a multi-center site plan for Kalytera’s planned clinical trials.

“Kalytera’s recent groundbreaking clinical trial with CBD as a treatment for GvHD generated a great deal of excitement at EBMT,” said Dr. Salzman. “The EBMT annual meeting brings together the world’s leading authorities in HCT, a lifesaving procedure for a number of diseases. HCT patients will benefit tremendously if the risk of GvHD can be substantially reduced.

“Based on the encouraging results from our Phase 2a studies, we believe that CBD has the potential to help patients with GvHD who routinely fail first-line therapy with steroids. Kalytera intends to undertake additional clinical studies in an effort to obtain regulatory approval to use CBD for the treatment and prevention of GvHD. Under Dr. Sagiv’s direction, we are working to complete our next, major clinical trial plan. We look forward to publishing the details of that plan this quarter.”

About GvHD and Kalytera’s CBD Clinical Research Program
GvHD is an FDA and EMEA-designated “orphan disease.” GvHD is a major cause of morbidity and mortality after HCT. It is a multisystem disorder that occurs when the transplanted cells from a donor (“the graft”) recognize the transplant recipient (“the host”) as foreign. Typically, only 60% of patients respond to first-line therapy with high-dose steroids. The 12-month mortality rate among patients with steroid-refractory Grade 3 and 4 GvHD exceeds 60% and 80%, respectively. In February 2017, Kalytera published results of a Phase 2a Clinical Study evaluating the safety and efficacy of CBD for treating Acute GvHD, with promising initial results.

About Kalytera
Kalytera (TSXV:KALY) is a clinical-stage pharmaceutical company pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and growing intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs – with an initial focus on Graft versus Host Disease (“GvHD”).

Kalytera is also developing a new class of proprietary cannabidiol (“CBD”) therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with CBD, including its poor oral bioavailability which greatly limits the efficacy of medical marijuana edible products that contain a high level of CBD. Kalytera is developing innovative CBD formulations and prodrugs intended for commercialization as FDA and EMEA-approved prescription medications in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera has filed composition of matter and method of use patents covering its novel inventions.

Company Contact
Robert Farrell
President, COO and CFO
Phone: (888) 861-2008

Forward-looking Statement Disclaimer
This news release may contain “forward-looking information” within the meaning of applicable securities laws. Although Kalytera believes in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because Kalytera can give no assurance that they will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release. Kalytera undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Kalytera, its securities, or its respective financial or operating results (as applicable). Kalytera disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Primary Logo

Copyright © 2017 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Fifty-Five Percent of Parents Who Took Out Loans For Kids’ College Owe $40,000 or More

News Image

It’s crucial for parents to carefully consider how helping their children pay for school will impact their own financial well-being. Sacrificing years of hard work and retirement savings just isn’t worth it.

The impact of rising student loan debt on today’s young college graduates is inarguably detrimental. One in seven Americans have delayed marriage due to student loan debt, while one in four had to postpone moving out of their parents’ homes.(1)

However, parents of these college students are just as negatively impacted, according to the latest survey by Student Loan Hero. The amount of debt parents report they have taken on, either through loans in their own name or by cosigning, often exceeds the average balance for Class of 2016 graduates:

43 percent have more than $30,000 in student loan debt
32 percent have more than $40,000 in student loan debt
23 percent have more than $50,000 in student loan debt

The survey also asked parents how often their child or children contribute payments toward the student loans borrowed to fund their educations. Thirty-nine percent indicated their child or children never contribute to student loan repayment, while 20 percent claimed they sometimes contribute. Forty-one percent said they receive no help from their child or children.


“It’s natural for parents to want to help out their children in any way possible, including covering the enormous cost of a college education,” said Andrew Josuweit, CEO of Student Loan Hero. “However, it’s crucial for parents to carefully consider how helping their children pay for school will impact their own financial well-being. Sacrificing years of hard work and retirement savings just isn’t worth it.”

Key Findings

Nearly three in 10 (27 percent) parents surveyed said they have withdrawn from retirement savings to help cover student loan payments.

Eighteen percent of parents surveyed regret taking out or cosigning loans for their child’s education.

Sixty-four percent of respondents have not considered having children refinance student loans into their own name; 16 percent were not aware this option exists.

Thirty-six percent of respondents said they would likely refinance their own loans if interest rates were expected to go up in the next year.

Fifty-six percent of respondents claimed they were not familiar with or aware of student loan repayment options such as Public Student Loan Forgiveness, income-contingent repayment, cosigner release, or refinancing loans into child’s name.

Seventeen percent of respondents claimed to be aware of the “Obama Student Loan Forgiveness” program – which is not a real student loan forgiveness program.

Survey Methodology

Survey was conducted via Google Consumer Surveys on behalf of Student Loan Hero on April 5-9, 2017, with a nationally representative sample of 1,001 adults living in the United States. “Are you currently making payments on student loans you cosigned for or took out for your child(ren)’s education?” was used as a screening question (with a target answer of “yes”).

About Student Loan Hero

Student Loan Hero combines easy-to-use tools with financial education to help the millions of Americans living with student loan debt manage and pay off their loans. Student Loan Hero has helped more than 150,000 borrowers manage and eliminate over $3 billion in student loan debt since 2012 and assists over 3.5 million people in becoming more financially healthy every year.

Student Loan Hero offers both current and former students free loan calculators, as well as unbiased, personalized advice and repayment plans through an easy-to-use online dashboard.
Founded in 2012 by CEO Andrew Josuweit, who himself had over $100,000 in student loans, Student Loan Hero operates on the belief that all loan help and recommendations should come with honesty and no hidden agenda.

For more information, visit

(1) “2015 Student Loan Burden Report,” Student Loan Hero, August 2015.

Share article on social media or email:

ASAP Invited to Speak at „Meet the Money” Conference in Los Angeles, CA

LOS ANGELES, CA – (NewMediaWire) – April 25, 2017 – ASAP Expo dba ASAP International Holdings (OTCQB: ASAE) today announced that the company’s CIO, Mr. Jerome Yuan, will present at the Meet the Money Conference held in Los Angeles on May 8-10, 2017. Jerome Yuan will be speaking on the „Chinese Investment: Debt and Equity” panel on Tuesday May 9th at 10:50am Session 6C.

Mr. Yuan is a featured speaker on the panel. This session will be moderated by Mr. Harry W Pflueger from MAXIM Hotel Brokerage. Other confirmed speakers for the forum include:

  • Alice Gao, ICBC (USA) NA, Senior VP & Head of Commercial Banking
  • Don Li, Interstate Hotels & Resorts, Head of Asia Investment Group
  • Frank J. Bergold, HSBC Bank USA, Senior Vice President
  • Grant Walker King, Hollywood International Regional Center, Managing Partner

Meet the Money® was founded in 1990 by Jim Butler, Chairman of JMBM’s Global Hospitality Group® — a legal and advisory team in the industry. With more than $71 billion in hotel transaction experience, involving more than 3,800 properties around the globe, the team’s extensive of the market and its players allows them to call on the industry’s top executives and thought leaders to share their insight and expertise at Meet the Money.

Jerome Yuan, CIO of ASAP International, stated, „I am honored to have the opportunity to participate in the top hotel conference in Los Angeles. Our involvement and invitation to Investment in Hospitality Forum validates our hard work helping overseas investors realize significant gains through real estate acquisitions in the U.S. in very short time.”

About ASAP International Holdings
ASAP is a holding company that operates real estate, investment banking and consulting for Chinese companies. Our mission is to be the bridge between China and the Western world. Our Real Estate division assists with institutional and high net-worth individuals with acquisition advisory and asset management. In past few years, ASAP is one of the most active hotel buyers in the U.S. and has consulted its clients with the successful acquisitions around 25 hotels with total value close to $1 Billion.

Corporate website

With the exception of historical information, the matters discussed in this news release include „forward-looking statements” within the meaning of the federal securities laws that are qualified by cautionary statements herein and in all company’s filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statement to conform the statement to actual results or changes in our expectations.

Automotive Glazing Market Overview, Top Manufacturers, Industry Growth Analysis and Forecast to 2022

PDF  View as PDF  Print View   

Automotive Glazing Market Analysis by Application (Sidelite, Sunroof, Backlite), Advanced Application (Large Windscreen, SunControl, Hydrophobic Glazing, HUD), Vehicle Type (On-Highway Vehicles, Off-Highway Vehicles) and Region – Forecast to 2022

Market Overview:

Glazing for Automotive Market is growing rapidly, owing to factors such as improved balanced climate and increased privacy, comfort, & reduced energy demands of customers. The factors such as increased security and enhanced aesthetics are expected to be factors that drive the Glazing for Automotive Market demand. The demand of the market is further expected to be driven by the integration of ultraviolet filter glass which can help in considerably extending the life of material and fabrics of the automobile. However, cost and complexity pertaining to glazing are projected to hinder the growth of the market.

Competitive Analysis-

Major Key Players in Glazing for Automotive Market are

o Pilkington Group Limited,
o Research Frontiers,
o American Glass Products,
o Fuyao Glass Industry Group Co. Ltd,
o Asahi Glass Co Ltd.,
o Central Glass Co. Ltd.,
o Guardian Industries Corporation,
o NordGlass,
o Pittsburgh Glass Works,
o LLC,
o Nippon Sheet Glass Company Ltd.

Access Report Details @

Market Research Analysis

Based on the advanced applications, hydrophobic glazing segment is expected to be the highest growing segment for glazing for automotive market, owing to features such as self-cleaning, reducing the foam in showers on the automobile windows. Other features such as anti-fogging, and acid resistance are also contributing to the growth of hydrophobic glazing for automotive.

Asia-Pacific region is expected to dominate the glazing for automotive market with the highest CAGR. Developing nations, in the region such as China and India are exhibiting a considerable growth due to growing health & safety concerns. The increase in demand of automotive due to the rise in the purchasing power, is also expected to contribute to the growth of this region

Access the market data and market information presented through more than 25 market data tables and 25 figures spread over 111 numbers of pages of the project report „Global Glazing for Automotive Market – Forecast to 2022”

Request a Sample Copy of Report @

Scope of the Report

This study provides an overview of the Global Glazing for automotive market, tracking three market segments across four geographic regions. The report studies key players, providing a five-year annual trend analysis that highlights market size, volume and share for North America, Europe, Asia Pacific (APAC) and Rest of the World (ROW). The report also provides a forecast, focusing on the market opportunities for the next five years for each region. The scope of the study segments the Global Glazing for automotive market by its application, advanced application, vehicle type and region.

List of Tables

TABLE 1 Global Glazing for Automotive Market, By Application
TABLE 2 Global Glazing for Automotive Market, By Advanced Application
TABLE 3 Global Glazing for Automotive Market, By Vehicle Type
TABLE 4 Global Glazing for Automotive Market, By Regions
TABLE 5 North America Glazing for Automotive Market, By Country
TABLE 6 North America Glazing for Automotive Market, By Application


About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact Info:
Name: Akash Anand
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India
Phone: +1 646 845 9312

Source URL:

For more information, please visit

Source: MarketersMedia

Release ID: 190084

Recent Press Releases By The Same User

Herbal Tea – Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022 (Tue 25th Apr 17)

EMC/EMI Testing Products Market 2017 Global Analysis, Opportunities and Forecast To 2022 (Tue 25th Apr 17)

Mixed Reality Market 2017 Global Trend, Segmentation and Opportunities Forecast To 2022 (Tue 25th Apr 17)

IOT Analytics Market is Streaming Fast & Expected To Reach At USD 18 billion by 2022 with CAGR of 25% (Tue 25th Apr 17)

Machine Learning as a Service (MLaaS) Market 2017 Global Analysis, Opportunities and Forecast To 2022 (Tue 25th Apr 17)

Automotive Sensors Market 2017 Global Analysis, Opportunities and Forecast To 2022 (Tue 25th Apr 17)

Cyrcadia, Inc. Prepares for iTBra™ Product Launch and Expands Strategic Operations to Asia

One of our objectives has been to launch Cyrcadia’s early breast cancer monitoring technology in Asia, where breast cancer is accelerating at twice the pace of the rest of the world

Cyrcadia, Inc.(CI) announced this week a strategic expansion to accelerate operations and market launch into Asia for early breast cancer monitoring. CI has entered into a License and Cooperation Agreement Cyrcadia Asia, Ltd. (CA), a newly formed company in Hong Kong which will serve as the base for the Asia market launch of CI’s proprietary iTBraTM technology expected to commence in late 2017 or early 2018 under the global CI brand of Cyrcadia Health.

Under the License and Cooperation Agreement, Cyrcadia Asia has exclusive marketing rights to the iTBra technology and products in Asia. CA will assume and fund certain further product development and other activities with respect to the iTBra technology and products for the benefit of both CI and CA. The License and Cooperation Agreement also provides for certain other financial terms between the two parties intended to enable the launch of the technology and products in Asia. CI retains exclusive marketing rights to the United States, Mexico and Canada, with the marketing strategy for the iTBra technology and products in other countries to be further discussed by the parties.

Having obtained U.S. FDA 510(k) Class II approval for its iTBra technology, CI has conducted clinical trials in the U.S. with its newly developed scalable product, which demonstrates greatly improved outcomes, beyond historical product results. CI’s predictive analytic artificial intelligence (AI) based technology now demonstrates 80%+ accuracy with a two-hour wear when compared with the original trials which required 48-hour wear and achieved 74% accuracy. CI and CA expect this greatly improved performance to support the use of the 510(k) approval to launch the technology and products into regulated countries in the near term.

CI’s proprietary early breast cancer monitoring technology is based on wearable sensor patches that are placed under a woman’s own garments and worn for two hours. The sensor data results processed through CI’s artificial intelligence (AI) lab, are automatically communicated to the patient, her physician and insurance company. Powered by this machine-learning process, the greater the population served by the CI AI technology, the more accurate the results become for future patients.

Cyrcadia’s 80%+ accuracy also compares very favorably to mammography which has a published accuracy of less than 50% for the densest of breast tissue. Tissue density, which leads to a higher propensity for cancer, affects 40% of the western population and up to 70% of the Asian population.

To ensure a successful launch in the Asia market, CI’s former CI CEO, Rob Royea has now assume the role of CEO for CA. CI’s co-founder, Matt Benardis, who has been serving in an operational role for CI, has assumed the role of CEO of CI, and initially will focus on the U.S. market with the launch by CI of the iTBra technology and products in the U.S., which CI expects to commence in the near term.

“One of our objectives has been to launch Cyrcadia’s early breast cancer monitoring technology in Asia, where breast cancer is accelerating at twice the pace of the rest of the world,” said Rob Royea, CEO CA. “With a much higher breast density population, virtually no nationalized screening initiatives, and the average age for breast cancer incident rate being approximately 20 years earlier than for those women in Europe and the U.S., a wearable technology such as Cyrcadia’s is addressing a clear and urgent need in Asia. There is great interest by several global insurance providers to partner with Cyrcadia Health in delivering our wearable monitoring to Asia expected by late 2017.”

“The License and Collaboration Agreement between CI and CA brings advantages for both parties,” said Royea. “The opportunity for early market entry and funding from the Asian operations brings additional funding into CI to exercise its option, under an Intellectual Property Asset Option Agreement with the technology’s developer to acquire directly certain patents which previously had been licensed to CI. Those patents are in the process of transferring to CI to be fully owned by CI, and they are licensed to CA under the License and Collaboration Agreement. Furthermore, the License and Collaboration Agreement allows for CI and CA to cooperate on global expansion of the intellectual property portfolio.”

Under the License and Collaboration Agreement, CI and CA have also established a joint venture, Cyrcadia Data Services, Ltd. to fund and develop the Cyrcadia health predictive analytics core lab. This entity will ensure improved accuracy in the technology as the companies feed in large volumes of data from their respective regions.

CI’s CEO Matt Benardis, sees the new structure as a win-win for all parties. “The new partnership with Cyrcadia Asia, Ltd. provides an accelerated speed to market globally,” said Benardis. “The Cyrcadia Health brand recognition that we can achieve together in large populations, along with the significant expansion of powerful intellectual property, is intended to maximize CI shareholder value as we move to our planned market launch here in North America. The joint venture of our unified predictive analytic core lab is intended to provide the highest possible accuracy for patients and providers of our technology throughout the world.”

About Cyrcadia
Cyrcadia, Inc. is a Nevada corporation, which uses the brand Cyrcadia Health with respect to its technology and products. The company was founded as First Warning Systems, Inc. in 2008, and is based in Reno, NV. The company’s product line is a device and software service originally licensed from Lifeline Biotechnologies, Inc. (OTC PINK: LLBO), that detects breast tissue abnormalities to enable health risk assessment and management including early breast cancer identification. Historic and current clinical testing has allowed proof of concept of the company’s iTBra technology and superior outcomes when compared to other diagnostic protocols. Cisco Systems, Inc. is underwritten the filming of a documentary about the evolution of the iTBra technology by Ironbound Films called „Detected Movie” to be released in Boston, MA on April 27, 2017. For further information, please visit and Cyrcadia Health at
Cyrcadia Asia, Ltd., a corporation incorporated in Hong Kong, is a licensee of Cyrcadia, Inc. with the exclusive right to use Cyrcadia Health branding in connection with, and to commercialize, the iTBra technology and products in Asia.

Cyrcadia Data Services, a joint venture between Cyrcadia, Inc. and Cyrcadia Asia, Ltd., as an Ireland-based corporation, the globally unified core lab operations of which will benefit from the data generated by iTBra technology patient screening populations into a single artificial intelligent database leading to ever-improving accuracy for the iTBra technology.

Share article on social media or email:

International Stem Cell Corp. (ISCO: OTCQB) | International Stem Cell Corporation Completes First Cohort In Parkinson’s Disease Clinical Trial

Apr 25, 2017

OTC Disclosure & News Service

CARLSBAD, Calif., April 25, 2017 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that the fourth (and final) patient in the first cohort of the clinical trial for Parkinson’s Disease (PD) was successfully transplanted with ISC-hpNSC® cells. The fourth operation went according to plan and no adverse events associated with ISC-hpNSC® have been reported in any of the patients.

Russell Kern, PhD, executive vice president and chief scientific officer of ISCO commented: „We are very encouraged by the early clinical safety data for ISC-hpNSC®. We look forward to dosing our second cohort with 50 million cells and enrolling the rest of our clinical trial participants in 2017. The Data Safety Monitor Board meeting will be held in the beginning of May and we expect to receive approval to start an accelerated enrollment of patients into the second cohort.”

There are no approved treatments that restore the damaged dopaminergic neurons. The death of dopaminergic neurons causes the motor symptoms associated with PD such as stiffness, slowness and tremor.  Based on our preclinical research, ISC-hpNSC® has the potential to provide neurotrophic support and neuroregeneration to the affected tissues of the recipient brain. ISC-hpNSC® is the world’s first pluripotent stem cell based therapy for PD and if successful, it would represent a paradigm shift in the treatment of this devastating disease.

About the clinical study

The Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranially transplanted into patients with moderate Parkinson’s disease. The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate to severe Parkinson’s disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals, to evaluate the safety and biologic activity of ISC-hpNSC®. PET scan will be performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC® will be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr and other rating scales. An extension phase of the study will evaluate patients every 6 months for 5 additional years.

About Parkinson’s disease

Parkinson’s disease (PD) is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson’s disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement-related; these symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease, and depression is the most common psychiatric symptom. Parkinson’s disease is more common in older people, with most cases occurring after the age of 50.

There are no approved treatments that restore the damaged dopaminergic neurons. Medications typically used in the treatment of Parkinson’s, L-DOPA and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective while at the same time frequently producing a complication marked by involuntary writhing movements. There are over 10 million people afflicted by PD worldwide. In 2013 PD resulted in about 103,000 deaths globally, up from 44,000 deaths in 1990.

About ISC-hpNSC®

International Stem Cell Corporation’s proprietary ISC-hpNSC® consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC® is a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are clear of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson’s disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC®. ISC-hpNSC® provides neurotrophic support and neuroregeneration to the dying dopaminergic neurons of the recipient PD brain. Additionally, ISC-hpNSC® is safe, well tolerated and does not cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSC® may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (, and stem cell-based skin care products through its subsidiary Lifeline Skin Care ( More information is available at

To subscribe to receive ongoing corporate communications, please click on the following link: 
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: and 

Safe harbor statement
Statements pertaining to anticipated developments, clinical studies expectations (including timing and results), progress of research and development, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as „will,” „believes,” „plans,” „anticipates,” „expects,” „estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company’s business, particularly those mentioned in the cautionary statements found in the company’s Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.


International Stem Cell Corporation
Russell Kern,PhD
Executive VP, 
Chief Scientific Officer
Phone: +1 760 940 6383

Primary Logo

Copyright © 2017 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Light Engine Design Corp. Confirms Reappointment of Kevin Stone as President and Chief Technology Officer

TEMPE, AZ – (NewMediaWire) – April 25, 2017 – Light Engine Design Corp. (OTC PINK: TLED) has confirmed the reappointment of Kevin Stone as President, Chief Technology Officer and Board Member of the Company effective April 1. He was originally appointed to this position about six months ago when the Company went public in a merger transaction. Mr. Stone brings with him a record of innovation and achievement.

Kevin Stone is founder of Dallas Lighting & Photonics, Inc. and is architect of DLP’s polyhedral array and laser phosphor technologies, as well as chief designer for Tall Trees’ new modular horticultural lighting. Kevin has over three decades of wide-ranging experience in the lighting industry. His broad experience ranges from designer and specifier to product and subsystem design for entertainment, architectural and military segments of the lighting industry. Kevin has worked with industry pioneers including VariLite, Syncrolite, Arri, and Rosco Labs in the development of such revolutionary products as Rosco’s DichroFilm color filters and Syncrolite’s OmniColor filtration technology. Kevin has been awarded patents for color-filtration and beam-shaping technologies. He is widely recognized as a pioneer in automated lighting design for his work on numerous concert tours, television shows and live productions.

„It is a rare opportunity to participate in a venture so focused on advancing the Solid State Lighting industry,” stated Mr. Stone. „I am honored to join a team whose combined talents and experience perfectly position the Company to meet the demands of the growing SSL industry with novel solutions and cutting edge innovation.”

About Light Engine Design Corp.
Light Engine Design Corp. (OTC PINK: TLED) is the parent company of wholly-owned subsidiaries Dallas Lighting & Photonics, Inc. and Tall Trees LED Company, Inc. The companies are focused on the development and sales of state-of-the-art Solid-State Lighting (SSL), specializing in advanced light engines employing unique LED and laser phosphor technologies across the lighting industry. For details, visit

Light Engine Design Corp Forward-Looking Statements
This press release contains „forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from the current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Light Engine Design’s business and Light Engine Design undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Consumer Reports Ranks Memorial’s Heart Care Tops In South Florida

News Image

“Consumer Reports recognition of the successful outcomes we’ve had for cardiac patients is an objective validation of what we’ve known for several years,” said Aurelio M. Fernandez, III, FACHE, President and CEO of Memorial Healthcare System.

There is no better place in South Florida to undergo two common heart surgeries than Memorial Regional Hospital, according to a special report in the May issue of Consumer Reports focused on heart health.

The magazine gave Memorial Regional Hospital its highest quality ranking for results achieved during and after coronary bypass and aortic valve replacement procedures.

Consumer Reports rated Memorial’s Cardiac and Vascular Institute “better than average,” the magazine’s highest possible ranking, based on data supplied by the Society of Thoracic Surgeons (STS). It was the only one in South Florida to earn that distinction and one of only 17 nationwide to earn the top mark for each of the surgeries.

(See the rankings for U.S. hospitals within the article at this link).

“STS has nearly 500 hospitals providing data on heart surgery performance for its registry,” said Dr. Doris Peter, director of the Health Rating Center for Consumer Health Choices at Consumer Reports. “Memorial Regional Hospital is among a very small percentage of those that have received the highest rating.”

Although not every hospital agrees to make its results public, Peter says the number of those being transparent about their performance is increasing. When her office began publishing STS data in their rankings, only 30% of facilities were willing to publicly report, a number that has doubled since 2010.

STS compiled data on isolated coronary heart bypass graft surgery from July 2015-June 2016 and measured survival rates, post-op complications, surgical technique, and drug usage. Aortic valve replacement information measured results between July 2013 and June 2016 and quantified survival and complication rates.

Memorial Cardiac and Vascular Institute’s TotalHEART surgeons performed more than 250 coronary artery bypass procedures during the period measured by STS data. It also performed 35 aortic valve replacements in 2015 and 22 operations where both procedures were performed at the same time. The bypass surgery involves grafting a blood vessel from the chest, legs, or arms to avoid a narrowed or blocked artery surrounding the heart. The valve replacement uses a mechanical or biological replacement for a damaged or diseased aortic valve.

“Consumer Reports recognition of the successful outcomes we’ve had for cardiac patients is an objective validation of what we’ve known for several years,” said Aurelio M. Fernandez, III, FACHE, President and CEO of Memorial Healthcare System. “We’ve embraced transparency as part of our patient and family-centered care model and want consumers to have accurate information when making healthcare decisions.”    

Memorial has been ranked in the top 1% of adult cardiac surgery programs in the U.S. and has a three-star rating from STS, its highest ranking. It also performed Broward County’s first adult heart transplant and was the first to establish an adult transplant program.    

Memorial Healthcare System (MHS) is one of the largest public healthcare systems in the country and a national leader in quality care and patient satisfaction. Its facilities include Memorial Regional Hospital, Memorial Regional Hospital South, Joe DiMaggio Children’s Hospital, Memorial Hospital West, Memorial Hospital Miramar, Memorial Hospital Pembroke, and the Memorial Manor nursing home. MHS has been recognized as one of Modern Healthcare magazine’s “Best Places to Work in Healthcare,” Florida Trend’s “Florida’s Best Companies to Work For,” and Becker’s Hospital Review’s “150 Great Places to Work in Healthcare.”

Share article on social media or email: